1421919-75-6

Basic information

• Product Name: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-
• Synonyms: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-;KPT-276;2-Propen-1-one, 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-1-(3,3-difluoro-1-azetidinyl)-, (2Z)-;(KPT276)(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one
• CAS NO: 1421919-75-6
• Molecular Formula: C₁₆H₁₀F₈N₄O
• Molecular Weight: 426.2640256
• EINECS: -0
• Product Categories: API;Inhibitors
• Mol File: 1421919-75-6.mol

Chemical Properties

• Boiling Point: 477.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.56±0.1 g/cm3(Predicted)
• Solubility: insoluble in EtOH; insoluble in H2O; ≥19.85 mg/mL in DMSO
• PKA: 0.59±0.50(Predicted)
• CAS DataBase Reference: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-(1421919-75-6)
• EPA Substance Registry System: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-(1421919-75-6)

Safety Data

• Hazardous Substances Data: 1421919-75-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3is used as a potential therapeutic agent for various diseases due to its unique molecular structure and properties. The triazole ring and trifluoromethyl groups may provide specific interactions with biological targets, making it a promising candidate for drug development.
Used in Chemical Research:
In the field of chemical research, (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3can be used as a starting material or intermediate for the synthesis of more complex molecules with potential applications in various industries, such as materials science, agrochemistry, and pharmaceuticals.
Used in Material Science:
The unique properties of (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3may also make it suitable for use in the development of new materials with specific characteristics, such as improved stability, reactivity, or selectivity. These materials could have applications in various industries, including electronics, coatings, and adhesives.

references

[1]. ranganathan p, yu x, na c, et al. preclinical activity of a novel crm1 inhibitor in acute myeloid leukemia. blood, 2012, 120(9): 1765-1773. [2]. schmidt j, braggio e, kortuem km, et al. genome-wide studies in multiple myeloma identify xpo1/crm1 as a critical target validated using the selective nuclear export inhibitor kpt-276. leukemia, 2013, 27(12): 2357-2365.

Upstream product

• 1388842-44-1 (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid 
• 1333154-10-1 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole 
• 288315-03-7 3,3-difluoroazetidine hydrochloride 
• 317319-15-6 3,5-bis(trifluoromethyl)benzothioamide 
• 27126-93-8 3,5-bis(trifluoromethyl)benzonitrile 
• 1333152-22-9 (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1421920-40-2 (Z)-1-(3,3-difluoroazetidin-1-yl)-3-iodoprop-2-en-1-one 

Relevant articles and documents

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of Structural Formulas (I), (II) and (III): or their pharmaceutically acceptable salts; pharmaceutical compositions comprising the compounds of Structural Formulas (I), (II) and (III); and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRMl activity. The values for the variables in Structural Formulas (I), (II) and (III) are as described and defined herein.

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.